A detailed history of State Street Corp transactions in Fate Therapeutics Inc stock. As of the latest transaction made, State Street Corp holds 5,252,974 shares of FATE stock, worth $11.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,252,974
Previous 5,338,689 1.61%
Holding current value
$11.4 Million
Previous $17.5 Million 5.0%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.12 - $5.57 $267,430 - $477,432
-85,715 Reduced 1.61%
5,252,974 $18.4 Million
Q2 2024

Aug 14, 2024

SELL
$3.26 - $7.08 $8.8 Million - $19.1 Million
-2,697,980 Reduced 33.57%
5,338,689 $17.5 Million
Q1 2024

May 15, 2024

BUY
$3.54 - $8.35 $21.9 Million - $51.6 Million
6,174,750 Added 331.63%
8,036,669 $59 Million
Q4 2023

Feb 14, 2024

SELL
$1.65 - $3.94 $676,509 - $1.62 Million
-410,006 Reduced 18.05%
1,861,919 $6.96 Million
Q3 2023

Nov 14, 2023

SELL
$2.02 - $5.04 $16.2 Million - $40.5 Million
-8,041,986 Reduced 77.97%
2,271,925 $4.82 Million
Q2 2023

Aug 14, 2023

SELL
$4.76 - $6.59 $21.5 Million - $29.8 Million
-4,516,173 Reduced 30.45%
10,313,911 $49.1 Million
Q1 2023

May 15, 2023

BUY
$4.24 - $11.12 $37.7 Million - $98.9 Million
8,894,625 Added 149.86%
14,830,084 $84.5 Million
Q4 2022

Feb 14, 2023

BUY
$9.86 - $23.83 $15.3 Million - $37 Million
1,552,825 Added 35.43%
5,935,459 $59.9 Million
Q3 2022

Nov 15, 2022

SELL
$21.04 - $36.06 $18.7 Million - $32 Million
-887,501 Reduced 16.84%
4,382,634 $98.2 Million
Q2 2022

Aug 15, 2022

BUY
$17.78 - $42.39 $32 Million - $76.2 Million
1,797,703 Added 51.77%
5,270,135 $131 Million
Q1 2022

May 16, 2022

BUY
$29.67 - $60.28 $22.4 Million - $45.4 Million
753,639 Added 27.72%
3,472,432 $135 Million
Q4 2021

Feb 14, 2022

BUY
$47.84 - $64.34 $16.1 Million - $21.7 Million
337,254 Added 14.16%
2,718,793 $159 Million
Q3 2021

Nov 15, 2021

BUY
$59.27 - $95.73 $19.4 Million - $31.3 Million
326,993 Added 15.92%
2,381,539 $141 Million
Q2 2021

Aug 16, 2021

BUY
$67.25 - $92.52 $4.8 Million - $6.6 Million
71,350 Added 3.6%
2,054,546 $178 Million
Q1 2021

May 17, 2021

SELL
$72.16 - $117.4 $8.96 Million - $14.6 Million
-124,177 Reduced 5.89%
1,983,196 $164 Million
Q4 2020

Feb 16, 2021

SELL
$38.09 - $100.95 $30.3 Million - $80.2 Million
-794,735 Reduced 27.38%
2,107,373 $192 Million
Q3 2020

Nov 10, 2020

SELL
$30.41 - $40.5 $6.07 Million - $8.08 Million
-199,533 Reduced 6.43%
2,902,108 $116 Million
Q2 2020

Aug 14, 2020

BUY
$20.21 - $35.23 $12.9 Million - $22.4 Million
636,102 Added 25.8%
3,101,641 $106 Million
Q1 2020

May 11, 2020

BUY
$17.28 - $31.88 $42.6 Million - $78.6 Million
2,465,539 New
2,465,539 $54.8 Million

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $210M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.